E
Entera Bio
Biotech & Life Sciences · Jerusalem, Israel · Founded 2009 · IPO 2018
Innovative oral protein and peptide therapies for chronic disease management, eliminating the need for injections MoreLess
Entera Bio is a clinical-stage global company addressing high unmet clinical needs by developing first-in-class, daily oral protein and peptide replacement therapies. These therapies are designed to improve the standard of care for patients managing chronic diseases, allowing them to live healthier lives without the need for injections. Entera Bio's lead program focuses on creating the first oral osteoanabolic bone-forming daily tablet to treat osteoporosis, a condition that predominantly affects women and currently relies on injectable treatments. The company operates in the biopharmaceutical market, targeting patients with chronic conditions who require ongoing treatment. Entera Bio's business model involves the research, development, and commercialization of these innovative oral therapies. Revenue is generated through product sales, partnerships, and potential licensing agreements. Keywords: oral therapies, protein replacement, peptide replacement, chronic diseases, osteoporosis, osteoanabolic, biopharmaceutical, non-injectable, clinical-stage, global healthcare.
Company overview
Entera Bio company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2009
- Headquarters
- Jerusalem, Israel
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 76.8
Valuation & funding
Entera Bio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Jul 2026 | $275M | — | BVF Partners | ↗ |
| PRIVATE PLACEMENT VCOther financing | Apr 2026 | $10M | — | BVF Partners | ↗ |
| PRIVATE PLACEMENT VCOther financing | Dec 2023 | $6.6M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Dec 2019 | $14M | — | Undisclosed | — |
| IPOOther financing | Jun 2018 | $0 | — | Undisclosed | — |
| EARLY VCOther financing | Oct 2017 | Undisclosed | — | ||
| EARLY VCOther financing | Jul 2016 | Pontifax Funds | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $42K | 0% | −$11M | -27378.6% |
| 2025 | $42K | -76.8% | −$11M | -27378.6% |
| 2024 | $181K | — | −$9.5M | -5270.2% |
| 2023 | $0 | -100% | −$8.8M | — |
| 2022 | $134K | -76.5% | −$13M | -9714.2% |
| 2021 | $571K | +56.4% | −$12M | -2130.3% |
| 2020 | $365K | — | −$11M | -3050.1% |
Growth signals
Entera Bio website traffic
Latest recorded traffic for Entera Bio is 5.6K monthly website visits, up 93.1% over the last three months. Entera Bio's team grew 4.8% over the past year.
Comparisons
Entera Bio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Entera Bio's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on Entera Bio's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Entera Bio has talent and traffic
team presence
In the news
Latest news about Entera Bio
Recent press, funding announcements, and product moves mentioning Entera Bio — open to read from the original sources.
Market sentiment
What the market is saying about Entera Bio
An AI-synthesized read of the highest-engagement posts about Entera Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Entera Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.